Venus Remedies Limited

Company Profile

Venus Remedies Limited had its IPO on under the ticker symbol VENUSREM.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Venus Remedies Limited has a staff strength of 998 employees.

Stock update

Shares of Venus Remedies Limited opened at ₹234 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹230.3 - ₹234.8, and closed at ₹230.85.

This is a -0.86% slip from the previous day's closing price.

A total volume of 2,790 shares were traded at the close of the day’s session.

In the last one week, shares of Venus Remedies Limited have increased by +0.81%.

Venus Remedies Limited's Key Ratios

Venus Remedies Limited has a market cap of ₹3.17 billion, indicating a price to book ratio of 0.5597 and a price to sales ratio of 0.4565.

In the last 12-months Venus Remedies Limited’s revenue was ₹5.08 billion with a gross profit of ₹2.25 billion and an EBITDA of ₹528.80 million. The EBITDA ratio measures Venus Remedies Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Venus Remedies Limited’s operating margin was 4.83% while its return on assets stood at 3.01% with a return of equity of 5.9%.

In Q2, Venus Remedies Limited’s quarterly earnings growth was a negative -82.9% while revenue growth was a negative 33.5%.

Venus Remedies Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

15.8954

PEG

Its diluted EPS in the last 12-months stands at ₹14.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Venus Remedies Limited’s profitability.

Venus Remedies Limited stock is trading at a EV to sales ratio of 0.4165 and a EV to EBITDA ratio of 4.4088. Its price to sales ratio in the trailing 12-months stood at 0.4565.

Venus Remedies Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹6.01 billion

Total Liabilities

₹825.70 million

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Venus Remedies Limited ended 2024 with ₹6.01 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹6.01 billion while shareholder equity stood at ₹4.60 billion.

Venus Remedies Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹825.70 million in other current liabilities, in common stock, ₹1.42 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹212.10 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹386.80 million.

Venus Remedies Limited’s total current assets stands at ₹3.23 billion while long-term investments were ₹0 and short-term investments were ₹537.10 million. Its net receivables were ₹766.60 million compared to accounts payable of ₹508.40 million and inventory worth ₹1.20 billion.

In 2024, Venus Remedies Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Venus Remedies Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹230.85

52-Week High

₹301.8

52-Week Low

₹145

Analyst Target Price

₹

Venus Remedies Limited stock is currently trading at ₹230.85 per share. It touched a 52-week high of ₹301.8 and a 52-week low of ₹301.8. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹257.89 and 200-day moving average was ₹205.25 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4580.7% of the company’s stock are held by insiders while 0.1% are held by institutions.